Skip to main content

In this Jan. 18, 2016, file photo, a female Aedes aegypti mosquito is pictured on the arm of a researcher at the University of Sao Paulo.

Andre Penner/AP

A Quebec City-based research team has received the green light to begin testing a Zika vaccine on humans.

The Universite Laval-based group says it is the first in Canada to be authorized by Health Canada and the U.S. Food and Drug Administration to begin clinical studies.

The researchers will work in conjunction with two research centres in the United States to develop a vaccine for the mosquito-borne virus.

Story continues below advertisement

They are looking for healthy adult volunteers to take part in the study.

Although most cases of Zika are fairly mild, the virus has been linked to miscarriages and birth defects in babies born to women who have been infected.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter